This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Febbo, P. G. Articles by Oh, W. K. Search for Related Content PubMed PubMed Citation Articles by Febbo, P. G. Articles by Oh, W. K.

Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer

Authors' Affiliations: ¹ Lank Center for Genitourinary Oncology, Department of Medical Oncology, ² Department of Pathology, ³ Department of Biostatistical Sciences, and ⁴ Department of Radiology, Dana-Farber Cancer Institute; ⁵ Division of Urologic Surgery, Brigham and Women's Hospital, Boston, Massachusetts and ⁶ Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Requests for reprints: William K. Oh, Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Phone: 617-632-3466; Fax: 617-632-2165; E-mail: william_oh{at}dfci.harvard.edu.

Purpose: To determine the clinical, pathologic, and molecular effects of neoadjuvant docetaxel chemotherapy in high-risk localized prostate cancer.

Experimental Design: Patients with biopsy Gleason scores of 8 to 10, serum prostate-specific antigen levels >20 ng/mL, and/or clinical stage T₃ disease received weekly docetaxel (36 mg/m²) for 6 months, followed by radical prostatectomy, and were monitored with weekly visits, serum prostate-specific antigen measurements, and endorectal magnetic resonance imaging (MRI). Frozen tumor specimens were collected for microarray analysis.

Results: The 19 patients enrolled received 82% of the planned chemotherapy. Toxicity was mild to moderate; fatigue and taste disturbance were common. Prostate-specific antigen declines of >50% were seen in 11 of 19 patients (58%; 95% confidence interval, 33-80%) and endorectal MRI showed maximum tumor volume reduction of at least 25% in 13 of 19 patients (68%; 95% confidence interval, 47-85%) and at least 50% in 4 patients (21%; 95% confidence interval, 6-46%). Sixteen patients completed chemotherapy and had radical prostatectomy; none achieved pathologic complete response. Microarray analysis identified coordinate up-regulation of genes involved in androgen metabolism associated with docetaxel therapy. Specifically, RNA expression for genes that decrease cellular levels of bioactive androgens was coordinately increased in response to chemotherapy.

Conclusions: Neoadjuvant docetaxel administered for 6 months before radical prostatectomy is feasible, well tolerated, and often results in prostate-specific antigen declines of >50% and decreased tumor volume on endorectal MRI. No pathologic complete responses were observed. Altered androgen metabolism may partially account for the noted declines in prostate-specific antigen and be a mechanism for chemotherapy resistance.

This article has been cited by other articles:

				P. Sooriakumaran, A. Henderson, P. Denham, and S. EM. Langley A Novel Method of Obtaining Prostate Tissue for Gene Expression Profiling International Journal of Surgical Pathology, June 1, 2009; 17(3): 238 - 243. [Abstract] [PDF]

				P. SOORIAKUMARAN, P. MACANAS-PIRARD, G. BUCCA, A. HENDERSON, S.E.M. LANGLEY, R.W. LAING, C.P. SMITH, E.E. LAING, and H.M. COLEY A Gene Expression Profiling Approach Assessing Celecoxib in a Randomized Controlled Trial in Prostate Cancer Cancer Genomics Proteomics, March 1, 2009; 6(2): 93 - 99. [Abstract] [Full Text] [PDF]

				D. Rathkopf, M. A. Carducci, M. J. Morris, S. F. Slovin, M. A. Eisenberger, R. Pili, S. R. Denmeade, M. Kelsen, T. Curley, M. Halter, et al. Phase II Trial of Docetaxel With Rapid Androgen Cycling for Progressive Noncastrate Prostate Cancer J. Clin. Oncol., June 20, 2008; 26(18): 2959 - 2965. [Abstract] [Full Text] [PDF]

				J. A. Garcia, E. A. Klein, C. Magi-Galluzzi, P. Elson, P. Triozzi, and R. Dreicer Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with Locally Advanced Prostate Carcinoma Clin. Cancer Res., May 15, 2008; 14(10): 3052 - 3059. [Abstract] [Full Text] [PDF]

				C.-Y. Huang, T. M. Beer, C. S. Higano, L. D. True, R. Vessella, P. H. Lange, M. Garzotto, and P. S. Nelson Molecular Alterations in Prostate Carcinomas that Associate with In vivo Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15 Clin. Cancer Res., October 1, 2007; 13(19): 5825 - 5833. [Abstract] [Full Text] [PDF]

				M. Mimeault, S. L. Johansson, G. Vankatraman, E. Moore, J.-P. Henichart, P. Depreux, M.-F. Lin, and S. K. Batra Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells Mol. Cancer Ther., March 1, 2007; 6(3): 967 - 978. [Abstract] [Full Text] [PDF]

				C. Priolo, D. Tang, M. Brahamandan, B. Benassi, E. Sicinska, S. Ogino, A. Farsetti, A. Porrello, S. Finn, J. Zimmermann, et al. The Isopeptidase USP2a Protects Human Prostate Cancer from Apoptosis. Cancer Res., September 1, 2006; 66(17): 8625 - 8632. [Abstract] [Full Text] [PDF]

				P. G. Febbo and P. W. Kantoff Noise and Bias in Microarray Analysis of Tumor Specimens J. Clin. Oncol., August 10, 2006; 24(23): 3719 - 3721. [Full Text] [PDF]

				M. Stanbrough, G. J. Bubley, K. Ross, T. R. Golub, M. A. Rubin, T. M. Penning, P. G. Febbo, and S. P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res., March 1, 2006; 66(5): 2815 - 2825. [Abstract] [Full Text] [PDF]

				P. G. Febbo, A. Thorner, M. A. Rubin, M. Loda, P. W. Kantoff, W. K. Oh, T. Golub, and D. George Application of Oligonucleotide Microarrays to Assess the Biological Effects of Neoadjuvant Imatinib Mesylate Treatment for Localized Prostate Cancer Clin. Cancer Res., January 1, 2006; 12(1): 152 - 158. [Abstract] [Full Text] [PDF]

				W. K. Oh High-Risk Localized Prostate Cancer: Integrating Chemotherapy Oncologist, October 1, 2005; 10(suppl_2): 18 - 22. [Abstract] [Full Text] [PDF]